| Date Filed | Type | Description |
| 10/10/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 10/10/2023 |
8-K/A
| Quarterly results |
| 10/06/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 10/06/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 10/06/2023 |
8-K
| Other Events Interactive Data |
| 08/25/2023 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/19/2023 |
S-4
| Form S-4 - Registration of securities, business combinations: |
| 07/06/2023 |
SC 13G
| RA CAPITAL MANAGEMENT, L.P. reports a 5.5% stake in TALARIS THERAPEUTICS, INC. |
| 07/05/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/05/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/01/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/30/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 04/27/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 04/21/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/14/2023 |
8-K
| Quarterly results |
| 03/31/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 10/20/2022 |
8-K
| Quarterly results |
| 08/26/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/15/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/15/2022 |
8-K
| Quarterly results|
Docs:
|
"Three months ended June 30, 2022 2021 Operating expenses Research and development $ 13,187 $ 7,570 General and administrative $ 5,228 $ 3,487 Total operating expenses 18,415 11,057 Loss from operations Interest and other income , net $ 319 $ Net loss attributable to common stockholders $ $ Net loss per common share, basic and diluted $ $ Weighted average number of common shares outstanding used in computation of net loss per common share, basic and diluted $ 41,088,085 $ 27,373,165 Balance Sheets Selected Financial Data June 30, December 31, 2022 2021 Cash, cash equivalents and marketable securities $ 207,112 $ 243,971 Working capital 204,706 238,527 Total assets 220,916 251,422 Other liabilities 2,822 626 Total liabilities 10,174 8,613 Total convertible preferred stock and stockholders’ ..." |
|
| 06/30/2022 |
8-K
| Quarterly results |
| 06/13/2022 |
8-K
| Quarterly results |
| 05/17/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/12/2022 |
8-K
| Quarterly results |
| 04/29/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/29/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
|